TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36802022
Drug: Palovarotene 10
Normalized name: palovarotene 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene 10 mg
Study: 36802022
Drug: Palovarotene (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palovarotene (both doses)
Study: 36802715
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg efpeglenatide
Study: 36802715
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg efpeglenatide
Study: 36803273
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (200,000 IU/1 ml of cholecalciferol)
Study: 36803273
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (physiological saline (1 ml))
Study: 36803647
Drug: Azithromycin-based two-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin-based two-drug therapy
Study: 36803647
Drug: Azithromycin-based three-drug
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin-based three-drug therapy
Study: 36803673
Drug: Evolutionary Systems
Normalized name: CENTELLA ASIATICA 0.3 mg in 3 TOPICAL CREAM [StemCell TeN 10 Revolutionary skin theraphy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolutionary Systems Therapy for Schizotypy (experimental treatment)
Study: 36803673
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy and psychopharmacological treatment (control)
Study: 36803737
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate solution (OCS) administered before surgery
Study: 36803737
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate solution (OCS)
Study: 36803835
Drug: Mindfulness-based intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness-based intervention (M-Body), eight weekly, 90-min group sessions
Study: 36803837
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Study: 36803837
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of post-surgical systemic antibiotic therapy for implant-free infections
Study: 36803837
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Study: 36803837
Drug: 12 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 12 weeks of post-surgical systemic antibiotic therapy for residual implant-related infections
Study: 36803837
Drug: Post-surgical systemic
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-surgical systemic antibiotic therapy
Study: 36803840
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks
Study: 36803840
Drug: Atezolizumab 1200
Normalized name: atezolizumab 1200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab 1200 mg IV every 3 weeks for ≤96 weeks + BCG (50 mg) induction and maintenance
Study: 36803840
Drug: BCG (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCG (50 mg) induction and maintenance
Study: 36803992
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral ivermectin (600 µg/kg daily for 7 days)
Study: 36803992
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies casirivimab and imdevimab (600 mg/600 mg)
Study: 37778363
Drug: No study
Approvals — FDA: no, EMA: no, PMDA: no
Description: No study drug
Study: 39748312
Drug: Zavegepant 10
Normalized name: zavegepant 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zavegepant 10 mg nasal spray
Study: 36804094
Drug: Baliforsen 100
Normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baliforsen 100 mg
Study: 36804094
Drug: Baliforsen 200
Normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baliforsen 200 mg
Study: 36804094
Drug: Baliforsen 300
Normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baliforsen 300 mg
Study: 36804094
Drug: Baliforsen 400
Normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baliforsen 400 mg
Study: 36804094
Drug: Baliforsen 600
Normalized name: Baliforsen
DrugBank: Baliforsen (DB17852)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baliforsen 600 mg
Study: 36804322
Drug: Moderate-dose group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-dose group (4 mg total carotenoids/d, 177 mL orange-carrot juice/d)
Study: 36804322
Drug: High-dose group
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose group (8 mg total carotenoids/d, 355 mL orange-carrot juice/d)
Study: 36804322
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (negligible carotenoids, 177 mL apple juice/d)
Study: 36804450
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (CC) intervention including motivational interviewing and behavioral activation for 12 months
Study: 36804834
Drug: BPaL regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPaL regimen (high-dose linezolid, bedaquiline, and pretomanid)
Study: 36805083
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy with AAV8-LSPhGAA (1.6 × 10^13 vg/kg)
Study: 36805095
Drug: Substantial protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Substantial protein (≥0.4 g/kg/d) or calorie (≥5 kcal/kg/d) gap between targeted or actual intake
Study: 37359884
Drug: Surf Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surf Therapy
Study: 37359884
Drug: Hike Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hike Therapy
Study: 36805672
Drug: Both Surf
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both Surf and Hike Therapies
Study: 36805707
Drug: Inhaled prostacyclin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled prostacyclin (3 times/day for 5 days)
Study: 36805833
Drug: Ato-Dro 80-5
Normalized name: SKIN BARRIER WIPE ATOS SKIN TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ato-Dro 80-5 mg
Study: 36805833
Drug: Ato-Dro 80-10
Normalized name: SKIN BARRIER WIPE ATOS SKIN TAC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ato-Dro 80-10 mg
Study: 36806068
Drug: Topical corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical corticosteroids (TCS) during an AD flare
Study: 36806073
Drug: Smartphone app
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Smartphone app (Airmid) with monthly questionnaires for 90 days
Study: 36807215
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) applied to the first and second molars for 10 seconds per point at 16 different points.
Study: 36807215
Drug: Contralateral side
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contralateral side of the intervention group (no laser treatment).
Study: 36807273
Drug: Ultra-long 48
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-long 48 mm drug-eluting stent (DES)
Study: 36807465
Drug: Ivermectin (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (600 μg/kg daily for 6 days)
Study: 36808045
Drug: Web-based cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Web-based cognitive-behavioral therapy
Study: 36808075
Drug: sitravatinib 120
Normalized name: Sitravatinib
DrugBank: Sitravatinib (DB15036)
Approvals — FDA: no, EMA: no, PMDA: no
Description: sitravatinib 120 mg orally once daily plus tislelizumab 200 mg intravenously every 3 weeks
Study: 36808074
Drug: hCART19 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hCART19 therapy
Study: 36808074
Drug: hCART19 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: hCART19 therapy with consolidation therapy
Study: 36808186
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (rifampin and isoniazid for 24 weeks with pyrazinamide and ethambutol for the first 8 weeks)
Study: 36808216
Drug: 12-g SCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-g SCF + 600-mg calcium lactate gluconate (SCF + Ca)
Study: 36808216
Drug: 12-g SCF
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12-g SCF
Study: 36808216
Drug: 600-mg calcium
Normalized name: ubidecarenone 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600-mg calcium lactate gluconate (Ca)
Study: 36808285
Drug: Nivolumab (NIVO)
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab (NIVO) 3 mg/kg every 2 weeks
Study: 36808285
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + Ipilimumab (NIVO + IPI) 3 mg/kg + 1 mg/kg every 3 weeks (4 doses) followed by NIVO 3 mg/kg every 2 weeks
Study: 36808891
Drug: Savolitinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib 600 mg (oral)
Study: 36808891
Drug: Intravenous 100
Normalized name: immune globulin intravenous 100 mg/mL intravenous solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous 100 μg of radiolabeled micro-tracer
Study: 36808931
Drug: d-mannose (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-mannose (2 g/d)
Study: 36808931
Drug: Control (Vaginal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (Vaginal Estrogen Therapy alone)
Study: 36809018
Drug: mSTART (Mobile
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSTART (Mobile SafeTy And Recovery Therapy)
Study: 36809018
Drug: START alone
Normalized name: Star Anise Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: START alone (without mobile augmentation)
Study: 36809018
Drug: mSTART and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: mSTART and START (regardless of mobile augmentation)
Study: 36809050
Drug: Savolitinib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Savolitinib (600 mg once daily) and Durvalumab (1,500 mg once every four weeks)
Study: 36809150
Drug: Serdexmethylphenidate/Dexmethylphenidate Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serdexmethylphenidate/Dexmethylphenidate Capsules
Study: 36809195
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg twice daily (BID)
Study: 36809195
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg once daily (OD)
Study: 36809195
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg BID (moderate-to-severe fatigue at baseline)
Study: 36809195
Drug: Setanaxib 400
Normalized name: Setanaxib
DrugBank: Setanaxib (DB16869)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Setanaxib 400 mg BID (mild fatigue at baseline)
Study: 36809247
Drug: Community-administered pre-referral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community-administered pre-referral rectal artesunate (RAS)
Study: 36809247
Drug: Parenteral antimalarial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral antimalarial and ACT administration
Study: 36809247
Drug: ACT administration
Normalized name: ACT-101
DrugBank: ACT-101 (DB17000)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACT administration at discharge
Study: 36809247
Drug: Parenteral artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Parenteral artesunate not followed up with oral ACT
Study: 36809321
Drug: Aspirin discontinuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin discontinuation (intervention group) until delivery
Study: 36809321
Drug: Aspirin continuation
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin continuation (control group) until 36 weeks of gestation
Study: 36809852
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (30 g); TID of AAs in whey was 97% ± 2.4% in humans and 97% ± 1.9% in pigs; if free AAs absorbed, TID would increase by 0.4%-units in humans and 0.1%-units in pigs.
Study: 36810101
Drug: Fluid balance
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluid balance control strategy (daily weight-driven restriction of fluid intake, diuretics administration, ultrafiltration if renal replacement therapy)
Study: 36810100
Drug: Correlation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation of metabolic changes among biological matrices
Study: 36810120
Drug: Modified Prolonged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Prolonged Exposure (mPE) therapy plus Treatment as Usual (TAU)
Study: 36810173
Drug: Antimicrobial stewardship
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial stewardship based on daily clinical assessment of clinical cure, allowing discontinuation of antibiotic therapy when at least three criteria of clinical cure are met.
Study: 36810173
Drug: Standard management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard management with a fixed duration of appropriate antibiotic therapy for 7 days according to international guidelines.
Study: 36810194
Drug: Ivermectin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400 mcg/kg) administered monthly for 3 months
Study: 36810194
Drug: Ivermectin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ivermectin (400 mcg/kg) plus livestock treatment with injectable ivermectin (200 mcg/kg) monthly for 3 months
Study: 36810194
Drug: Albendazole (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albendazole (400 mg) monthly for 3 months
Study: 36810788
Drug: Ustekinumab or
Normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ustekinumab or TNF inhibitor (TNFi)
Study: 36810939
Drug: Intranasal dexmedetomidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine-based regimens (most common dose 3 to 3.9 mcg/kg)
Study: 36810939
Drug: Intranasal dexmedetomidine-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal dexmedetomidine-based regimens
Study: 36810945
Drug: Low-dose glucocorticoids
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose glucocorticoids (≤ 7.5mg/day prednisone)
Study: 36811311
Drug: GLP-1, OXM,
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1, OXM, PYY (GOP) infusion for 4 weeks
Study: 36811382
Drug: WNT974 +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WNT974 + encorafenib + cetuximab (COMBO10: 10 mg, COMBO7.5: 7.5 mg, COMBO5: 5 mg)
Study: 36811557
Drug: cBMA augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: cBMA augmentation
Study: 36811846
Drug: Bilastine 0.6%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilastine 0.6% ophthalmic solution
Study: 36811937
Drug: Layperson-facilitated internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home), 10-week intervention
Study: 36811937
Drug: Layperson-facilitated internet-delivered
Normalized name: DELIVER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Layperson-facilitated internet-delivered cognitive behavioral therapy (Empower@Home)
Study: 36811949
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg subcutaneously every 4 weeks for 16 weeks
Study: 36811991
Drug: Intravenous ferric
Normalized name: Ferric Oxide
DrugBank: Ferric oxide (DB11576)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous ferric carboxymaltose (FCM) 500 mg administered <48 hours before surgery
Study: 36812121
Drug: Routine daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine daily physical activity (control)
Study: 36812434
Drug: Etranacogene dezaparvovec
Normalized name: Etranacogene dezaparvovec
DrugBank: Etranacogene dezaparvovec (DB16791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etranacogene dezaparvovec gene therapy (AAV5 vector expressing Padua factor IX variant)
Study: 39341368
Drug: Etranacogene dezaparvovec
Normalized name: Etranacogene dezaparvovec
DrugBank: Etranacogene dezaparvovec (DB16791)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etranacogene dezaparvovec gene therapy
Study: 36812433
Drug: Valoctocogene roxaparvovec
Normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valoctocogene roxaparvovec therapy (single infusion of 6×10^13 vg/kg)
Study: 36812433
Drug: Valoctocogene roxaparvovec
Normalized name: Valoctocogene roxaparvovec
DrugBank: Valoctocogene roxaparvovec (DB15561)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valoctocogene roxaparvovec therapy
Study: 36812616
Drug: Sensor-derived daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-derived daily activity
Study: 36812723
Drug: AFD-specific treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFD-specific treatment
Study: 36812894
Drug: Enhanced nutrition
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced nutrition protocol (early initiation of intralipids and faster advancement of glucose infusion rate)
Study: 36813084
Drug: W-SUDs (relational
Approvals — FDA: no, EMA: no, PMDA: no
Description: W-SUDs (relational agent)
Study: 36813086
Drug: Electronic peer
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic peer navigation (peer support via phone and automated monthly text messages)
Study: 36813284
Drug: Multifaceted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted antibiotic stewardship intervention
Study: 36813496
Drug: TCP-25 gel
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: TCP-25 gel (topical application on suction blister wounds)
Study: 36813496
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel (topical application on suction blister wounds)
Study: 36813503
Drug: Inhaled ciclesonide
Normalized name: ciclesonide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled ciclesonide 320 µg two times a day for 14 days
Study: 36813504
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine hydrochloride 5 mg/g ear drops (Otalgan) one to two drops up to six times daily for a maximum of 7 days in addition to usual care (oral analgesics, with/without antibiotics)
Study: 36813504
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (oral analgesics, with/without antibiotics)
Study: 36813747
Drug: SH-1028 200
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH-1028 200 mg once daily
Study: 36813747
Drug: SH-1028 240
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH-1028 240 mg cohort
Study: 36813747
Drug: SH-1028 300
Normalized name: Glutathione-SH
DrugBank: Glutathione (DB00143)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SH-1028 300 mg cohort
Study: 36813867
Drug: Concomitant nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concomitant nab-paclitaxel + gemcitabine chemotherapy
Study: 36813867
Drug: Sequential nab-paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sequential nab-paclitaxel + gemcitabine chemotherapy
Study: 36814246
Drug: Targeted therapies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted therapies (13 EMA-approved drugs)
Study: 36814898
Drug: Serclutamab talirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serclutamab talirine (Ser-T) monotherapy at doses up to 50 μg/kg, followed by 25 μg/kg Q4W
Study: 36814898
Drug: Serclutamab talirine
Normalized name: Loncastuximab tesirine
DrugBank: Loncastuximab tesirine (DB16222)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Serclutamab talirine (Ser-T) at recommended phase II dose (RP2D)
Study: 37709999
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with therapy
Study: 36815261
Drug: Mental health
Normalized name: MENS HEALTH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mental health Narrative Community-Based Group Therapy (NCGT)
Study: 36815322
Drug: 3HP therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3HP therapy (weekly rifapentine plus isoniazid)
Study: 36816341
Drug: Polypill therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polypill therapy (combination of ≥2 blood pressure medications and a statin with or without aspirin)
Study: 36816343
Drug: Icotinib (125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Icotinib (125 mg, three times daily for 12 months)
Study: 36816342
Drug: Vixarelimab 360
Normalized name: Vixarelimab
DrugBank: Vixarelimab (DB16350)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vixarelimab 360 mg weekly (720 mg loading dose)
Study: 36816574
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (SBP goals of 110-130 mmHg)
Study: 36816574
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (SBP goals of 130-150 mmHg)